Betoptic: Uses, Dosage & Side Effects

What Is Betoptic and What Is It Used For?

Betoptic contains the active substance betaxolol, a selective beta-1 adrenergic receptor antagonist. When applied topically to the eye, betaxolol reduces intraocular pressure (IOP) by decreasing the production of aqueous humor – the clear fluid that continuously circulates within the anterior (front) chamber of the eye. Elevated intraocular pressure is the primary modifiable risk factor for glaucoma, a progressive optic neuropathy that can lead to irreversible vision loss if left untreated. By lowering IOP, Betoptic helps protect the optic nerve from further damage.

Open-angle glaucoma is the most common form of glaucoma worldwide, accounting for approximately 70–90% of all glaucoma cases. In this condition, the drainage angle of the eye remains open, but the trabecular meshwork (the eye’s natural drainage system) becomes less efficient at draining aqueous humor over time. This gradual reduction in outflow leads to a buildup of fluid and a corresponding increase in intraocular pressure. Because the disease typically progresses slowly and painlessly, many patients are unaware they have it until significant vision loss has already occurred. According to the World Health Organization (WHO), glaucoma is the second leading cause of blindness globally, affecting an estimated 80 million people worldwide.

Betaxolol is classified as a selective beta-1 blocker, which distinguishes it from non-selective ophthalmic beta-blockers such as timolol (which blocks both beta-1 and beta-2 receptors). This selectivity is clinically relevant because beta-2 receptors are predominantly found in the smooth muscle of the airways. By preferentially blocking beta-1 receptors, betaxolol has a substantially reduced effect on bronchial smooth muscle compared to non-selective agents. Multiple clinical studies, including the landmark Betaxolol vs. Timolol Study Group trials published in the American Journal of Ophthalmology, have demonstrated that betaxolol produces fewer pulmonary side effects while still achieving clinically meaningful reductions in intraocular pressure, typically lowering IOP by 20–25% from baseline.

Betoptic is available in two formulations: Betoptic (betaxolol hydrochloride 0.5% ophthalmic solution) and Betoptic S (betaxolol hydrochloride 0.25% ophthalmic suspension). The suspension formulation (Betoptic S) was developed to provide equivalent IOP-lowering efficacy at half the concentration, which may result in better ocular comfort and reduced stinging upon instillation. Both formulations contain benzalkonium chloride as a preservative.

The onset of action for Betoptic occurs within approximately 30 minutes after topical application. The maximum pressure-lowering effect is typically achieved within 2 hours, and the therapeutic effect persists for approximately 12 hours. This pharmacokinetic profile supports the standard twice-daily dosing schedule. It may take up to four weeks of consistent use before intraocular pressure stabilizes at a new, lower level. During this initial period, your ophthalmologist will monitor your eye pressure regularly to assess the treatment response and determine whether dose adjustments or additional medications are needed.

Betoptic is sometimes used in combination with other classes of glaucoma medications, such as prostaglandin analogs (e.g., latanoprost, travoprost), carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide), alpha-agonists (e.g., brimonidine), or miotic agents. Combination therapy is often necessary when a single medication does not achieve the target IOP. When using multiple eye drops, it is important to wait at least 5 minutes between applications, and eye ointments should be applied last.

What Should You Know Before Using Betoptic?

Contraindications

Betoptic must not be used in certain clinical situations. Understanding these absolute contraindications is essential before beginning treatment with this medication.

• Hypersensitivity: Do not use Betoptic if you are allergic to betaxolol, other beta-blockers, or any of the inactive ingredients in the formulation (including benzalkonium chloride, disodium edetate, sodium chloride, hydrochloric acid/sodium hydroxide for pH adjustment, and purified water).
• Severe asthma or severe COPD: Betoptic is contraindicated in patients with severe bronchial asthma or severe chronic obstructive pulmonary disease (COPD). While betaxolol’s beta-1 selectivity reduces the risk of bronchospasm compared to non-selective beta-blockers, it is not eliminated entirely, and these patients are at significantly increased risk of life-threatening airway obstruction.
• Sinus bradycardia: Patients with abnormally slow heart rate should not use Betoptic, as beta-blockers can further reduce heart rate.
• Heart failure: Betoptic is contraindicated in patients with decompensated (uncontrolled) heart failure, as beta-blockers can worsen cardiac function in this setting.
• Heart block: Patients with second-degree or third-degree atrioventricular (AV) block should not use this medication, as beta-blockers can further impair cardiac conduction.

Warnings and Precautions

Before starting Betoptic, it is important to inform your prescribing physician about your complete medical history. The following conditions require careful consideration and may necessitate closer monitoring during treatment:

• Coronary artery disease: Patients with ischemic heart disease (symptoms may include chest pain, chest tightness, shortness of breath, or a feeling of suffocation) should be monitored closely. Although topical ophthalmic beta-blockers produce lower systemic levels than oral formulations, some degree of cardiovascular effect may still occur through systemic absorption.
• Heart rhythm disorders: Patients with existing cardiac conduction abnormalities, including first-degree AV block or sick sinus syndrome, should use Betoptic with caution as it may further slow cardiac conduction.
• Low blood pressure: Beta-blockers can potentially lower blood pressure. Patients with pre-existing hypotension should be monitored, particularly when initiating therapy.
• Mild to moderate respiratory disease: While betaxolol’s beta-1 selectivity provides a relative advantage over non-selective agents, patients with mild to moderate asthma, COPD, or other respiratory conditions should still be monitored for any worsening of respiratory symptoms. The European Glaucoma Society guidelines recommend betaxolol as the preferred topical beta-blocker when a beta-blocker is needed in patients with mild respiratory compromise.
• Peripheral vascular disease: Patients with conditions affecting blood circulation such as Raynaud’s disease or Raynaud’s syndrome may experience worsening of symptoms with beta-blocker therapy.
• Diabetes mellitus: Beta-blockers can mask the signs and symptoms of hypoglycemia (low blood sugar), particularly tachycardia and tremor. Patients with diabetes should be informed of this risk and monitor their blood glucose more carefully during treatment.
• Hyperthyroidism: Beta-blockers can mask the clinical signs of thyrotoxicosis (overactive thyroid). Abrupt withdrawal may precipitate a thyroid storm. Patients with known or suspected hyperthyroidism should be monitored accordingly.
• Myasthenia gravis: This neuromuscular condition can be exacerbated by beta-blockers. Patients with myasthenia gravis should use Betoptic with caution and under close medical supervision.
• Corneal disease: Betoptic may contribute to dry eye, and patients with pre-existing corneal disorders should be monitored. Ophthalmic beta-blockers have been associated with decreased corneal sensitivity.
• Previous glaucoma surgery: If you have undergone filtration surgery for glaucoma, discuss this with your doctor, as the dynamics of aqueous humor flow may be altered.

If you are scheduled for surgery under general anesthesia, inform your anesthesiologist that you are using Betoptic. Betaxolol may alter the effects of anesthetic agents and could cause additive myocardial depression. The decision to withdraw Betoptic before surgery should be made by your doctors on a case-by-case basis.

Pregnancy and Breastfeeding

Betoptic should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus. Beta-blockers, including betaxolol, may cross the placental barrier, and neonatal effects such as bradycardia, hypotension, respiratory distress, and hypoglycemia have been reported with systemic beta-blocker use during pregnancy. If Betoptic is used during pregnancy or if you become pregnant while using this medication, your doctor will carefully weigh the risks and benefits.

Betaxolol may be excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the medication, taking into account the importance of the drug to the mother. If you are breastfeeding or planning to breastfeed, consult your doctor before using Betoptic.

Driving and Operating Machinery

Betoptic may cause temporary blurred vision after instillation. If this occurs, do not drive or operate machinery until your vision has cleared. You are responsible for assessing your fitness to drive or perform tasks requiring alertness. The side effects of any medication may affect these abilities, so read all the information in this article for guidance and discuss any concerns with your doctor or pharmacist.

Important Information About Benzalkonium Chloride

Betoptic contains benzalkonium chloride as a preservative (0.1 mg/mL, equivalent to 0.5 mg per 5 mL bottle). This preservative has several important clinical implications:

• Contact lenses: Benzalkonium chloride can be absorbed by soft contact lenses and may cause discoloration. Remove soft contact lenses before applying Betoptic and wait at least 15 minutes before reinserting them.
• Eye irritation: This preservative can be irritating to the eyes, particularly in patients with dry eye syndrome or corneal disease. If you experience persistent irritation, stinging, or pain in the eye after applying the drops, contact your doctor. Preservative-free alternatives may be available in some markets.
• Long-term use: Prolonged exposure to benzalkonium chloride has been associated with ocular surface toxicity, particularly in patients using multiple preserved eye drop medications. Your ophthalmologist may recommend preservative-free formulations if long-term multi-drug therapy is required.

How Does Betoptic Interact with Other Drugs?

Although Betoptic is applied topically to the eye, a proportion of the drug is absorbed systemically through the nasal mucosa and conjunctival blood vessels. This systemic absorption, though generally lower than with oral beta-blockers, can lead to clinically relevant interactions with other medications, particularly those affecting the cardiovascular system. Proper nasolacrimal occlusion (pressing on the inner corner of the eye) after application significantly reduces systemic absorption and the potential for drug interactions.

Major Interactions

Minor Interactions

The risk of systemic interactions with Betoptic is generally lower than with non-selective ophthalmic beta-blockers like timolol, owing both to betaxolol’s lower systemic bioavailability and its beta-1 selectivity. Nevertheless, patients taking multiple cardiovascular medications should be monitored regularly. If you are using other eye drop medications, always maintain at least a 5-minute interval between different drops to ensure proper absorption. Eye ointments should always be applied last.

What Is the Correct Dosage of Betoptic?

Always use Betoptic exactly as prescribed by your doctor or as directed by your pharmacist. The dose should be individualized based on your response to treatment. Your ophthalmologist will regularly measure your intraocular pressure to determine whether the current dosing regimen is achieving the target pressure.

Adults (Including Elderly)

Children

How to Apply Betoptic Correctly

Proper instillation technique is essential for maximizing the therapeutic effect while minimizing systemic absorption and side effects. Follow these steps carefully each time you use Betoptic:

1. Wash your hands thoroughly with soap and water before handling the bottle.
2. Check the safety collar: If the safety collar on the bottle is loose when you first remove the cap, remove it before use.
3. If using Betoptic S (suspension): Shake the bottle gently before each use to ensure the medication is evenly mixed.
4. Tilt your head back and look up at the ceiling, or lie down and look upward.
5. Pull down the lower eyelid gently with a clean finger to create a small pocket between the eyelid and the eye.
6. Hold the bottle upside down between your thumb and middle finger. Position the dropper tip close to the eye without touching it.
7. Squeeze gently to release one drop into the pocket formed by the lower eyelid. The bottle is designed so that a light press on the bottom is sufficient.
8. Close your eye gently (do not blink vigorously) and press your finger firmly against the inner corner of the eye near the nose (nasolacrimal occlusion) for at least 2 minutes. This critically important step prevents the medication from draining through the tear duct into the nasal passages, where it would be rapidly absorbed into the bloodstream.
9. If treating both eyes, repeat steps 4–8 for the other eye.
10. Replace the cap tightly on the bottle immediately after use.

Missed Dose

If you forget to apply a dose of Betoptic, use it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not apply a double dose to make up for a missed one. Doubling the dose will not provide additional benefit and may increase the risk of side effects.

Overdose

If you accidentally apply too many drops of Betoptic to the eye, rinse your eye(s) thoroughly with lukewarm tap water. Do not apply additional drops until your next scheduled dose. Possible symptoms of overdose or excessive systemic absorption may include unusually slow heart rate (bradycardia), low blood pressure (hypotension), heart failure, and breathing difficulties (bronchospasm).

If Betoptic is accidentally ingested (for example, by a child), seek immediate medical attention or contact your local poison control center. Oral ingestion of ophthalmic beta-blocker solutions can produce significant systemic toxicity, particularly in children.

What Are the Side Effects of Betoptic?

Like all medicines, Betoptic can cause side effects, although not everybody gets them. Most side effects associated with Betoptic are mild and confined to the eye. However, because some betaxolol is absorbed systemically, side effects similar to those seen with oral beta-blockers may occur, albeit at a lower frequency. You can usually continue using the drops unless the side effects are severe. Speak with your doctor or pharmacist if you are concerned. Do not stop using Betoptic without consulting your doctor first.

The following side effects have been reported with Betoptic:

Systemic Side Effects of Ophthalmic Beta-Blockers

As with all ophthalmic beta-blockers, betaxolol is absorbed into the bloodstream to some extent. This systemic absorption can cause side effects similar to those seen with oral or injectable beta-blockers, although the incidence is generally lower. The following side effects have been reported across the class of ophthalmic beta-blockers and may occur with Betoptic:

• Allergic reactions: Systemic allergic responses including angioedema (swelling under the skin, potentially affecting the face, arms, and legs, which can make it difficult to swallow and breathe), urticaria (hives), localized or generalized rash, itching, and in rare cases, severe life-threatening anaphylactic reactions.
• Metabolic: Low blood sugar levels (hypoglycemia), which may not be recognized because common warning signs are masked by beta-blockade.
• Neurological: Nightmares, memory loss, stroke, decreased cerebral blood flow, worsening of myasthenia gravis symptoms, and abnormal skin sensations (paresthesia such as tingling and prickling).
• Ocular: Detachment of the choroid (the blood vessel-containing membrane beneath the retina) after filtration surgery, which may cause visual disturbances; decreased corneal sensitivity; corneal erosion; drooping upper eyelid (ptosis); and double vision (diplopia).
• Cardiovascular: Chest pain, palpitations, edema (fluid retention), chronic heart failure, cardiac arrhythmias, heart attack, and cardiac failure.
• Vascular: Raynaud’s phenomenon, cold hands and feet due to impaired peripheral circulation.
• Respiratory: Bronchospasm (predominantly in patients with pre-existing bronchospastic disease).
• Gastrointestinal: Indigestion (dyspepsia), diarrhea, dry mouth, abdominal pain, and vomiting.
• Skin: Psoriasiform rash (silvery-white scaling rash) or worsening of existing psoriasis.
• Musculoskeletal: Muscle pain (myalgia) not caused by exercise.
• Reproductive: Sexual dysfunction.
• General: Fatigue.

To minimize the risk of systemic side effects, always perform nasolacrimal occlusion (pressing on the inner corner of the eye near the nose for 2 minutes) after instilling the drops. This simple technique can reduce systemic absorption by up to 60% according to pharmacokinetic studies.

How Should You Store Betoptic?

Proper storage of Betoptic is essential to maintain the sterility, potency, and safety of the medication. Follow these guidelines carefully:

• Keep out of reach and sight of children. Store the bottle in a secure location where children cannot access it.
• Store in the original carton to protect from light. Betaxolol is sensitive to light and may degrade if exposed to prolonged direct sunlight or strong artificial light.
• Do not store above 25°C (77°F). Do not freeze.
• Do not use after the expiry date printed on the carton and bottle label. The expiry date refers to the last day of that month.
• Once opened: The in-use shelf life is 4 weeks for a single patient and 1 week when used for multiple patients (e.g., in a hospital setting). Discard the bottle once this period has passed, even if there is solution remaining, to reduce the risk of microbial contamination.
• Disposal: Do not dispose of medications via the drain or in household waste. Return unused or expired medications to your pharmacist for safe disposal. These measures help protect the environment.

What Does Betoptic Contain?

Active Ingredient

Each milliliter of Betoptic ophthalmic solution contains betaxolol hydrochloride equivalent to 5 mg of betaxolol (0.5% concentration). Betoptic S ophthalmic suspension contains betaxolol hydrochloride equivalent to 2.5 mg of betaxolol per mL (0.25% concentration).

Inactive Ingredients

• Benzalkonium chloride – preservative (0.1 mg/mL)
• Disodium edetate (EDTA) – chelating agent
• Sodium chloride – tonicity agent
• Hydrochloric acid and/or sodium hydroxide – pH adjustment
• Purified water – vehicle

Appearance and Packaging

Betoptic ophthalmic solution is a clear, colorless liquid supplied in a 5 mL polyethylene dropper bottle with a polyethylene screw cap. Betoptic S ophthalmic suspension is a white to off-white suspension in a similar bottle format. The bottle is designed with a controlled-drop tip that delivers a consistent drop size with gentle pressure on the bottom of the bottle.

Available pack size: 1 × 5 mL.